Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleSystemic Sclerosis

Esophageal Dilation and Other Clinical Factors Associated With Pulmonary Function Decline in Patients With Systemic Sclerosis

Kimberly Showalter, Aileen Hoffmann, Carrie Richardson, David Aaby, Jungwha Lee, Jane Dematte, Rishi Agrawal, Hatice Savas, Xiaoping Wu, Rowland W. Chang and Monique Hinchcliff
The Journal of Rheumatology December 2021, 48 (12) 1830-1838; DOI: https://doi.org/10.3899/jrheum.210533
Kimberly Showalter
1K. Showalter, MD, Northwestern University Feinberg School of Medicine, Department of Medicine, Chicago, Illinois, and Hospital for Special Surgery, Department of Medicine, Division of Rheumatology, New York, New York;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kimberly Showalter
Aileen Hoffmann
2A. Hoffmann, MS, Northwestern University Feinberg School of Medicine, Department of Medicine, Division of Rheumatology, Chicago, Illinois;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carrie Richardson
3C. Richardson, MD, Northwestern University Feinberg School of Medicine, Department of Medicine, Chicago, Illinois;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Aaby
4D. Aaby, MS, Northwestern University Feinberg School of Medicine, Department of Preventive Medicine, Chicago, Illinois;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jungwha Lee
5J. Lee, PhD, MPH, Northwestern University Feinberg School of Medicine, Department of Preventive Medicine, and Institute for Public Health and Medicine, Chicago, Illinois;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jane Dematte
6J. Dematte, MD, MBA, Northwestern University Feinberg School of Medicine, Department of Medicine, Division of Pulmonary and Critical Care Medicine, Chicago, Illinois;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rishi Agrawal
7R. Agrawal, MD, H. Savas, MD, Northwestern University Feinberg School of Medicine, Department of Radiology, Chicago, Illinois;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hatice Savas
7R. Agrawal, MD, H. Savas, MD, Northwestern University Feinberg School of Medicine, Department of Radiology, Chicago, Illinois;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaoping Wu
8X. Wu, MD, MS, New York Presbyterian/Weill Cornell, Department of Medicine, Division of Pulmonary and Critical Care Medicine, New York, New York;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rowland W. Chang
9R.W. Chang, MD, MPH, Northwestern University Feinberg School of Medicine, Department of Medicine, Division of Rheumatology, Department of Preventive Medicine, and Institute for Public Health and Medicine, Chicago, Illinois;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Monique Hinchcliff
10M. Hinchcliff, MD, MS, Northwestern University Feinberg School of Medicine, Department of Medicine, Division of Rheumatology, Chicago, Illinois, and Yale School of Medicine, Department of Medicine, Section of Rheumatology, Allergy & Immunology, New Haven, Connecticut, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Monique Hinchcliff
  • For correspondence: monique.hinchcliff@yale.edu
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective To identify clinical factors, including esophageal dilation on chest high-resolution computed tomography (HRCT), that are associated with pulmonary function decline in patients with systemic sclerosis (SSc).

Methods Patients fulfilled 2013 SSc criteria and had ≥ 1 HRCT and ≥ 2 pulmonary function tests (PFTs). According to published methods, widest esophageal diameter (WED) and radiographic interstitial lung disease (ILD) were assessed, and WED was dichotomized as dilated (≥ 19 mm) vs not dilated (< 19 mm). Clinically meaningful PFT decline was defined as % predicted change in forced vital capacity (FVC) ≥ 5 and/or diffusion capacity for carbon monoxide (DLCO) ≥ 15. Linear mixed effects models were used to model PFT change over time.

Results One hundred thirty-eight patients with SSc met the study criteria: 100 (72%) had radiographic ILD; 49 (35%) demonstrated FVC decline (median follow-up 2.9 yrs). Patients with antitopoisomerase I (Scl-70) autoantibodies had 5-year FVC% predicted decline (–6.33, 95% CI –9.87 to –2.79), whereas patients without Scl-70 demonstrated 5-year FVC stability (+1.78, 95% CI –0.59 to 4.15). Esophageal diameter did not distinguish between those with vs without FVC decline. Patients with esophageal dilation had statistically significant 5-year DLCO% predicted decline (–5.58, 95% CI –10.00 to –1.15), but this decline was unlikely clinically significant. Similar results were observed in the subanalysis of patients with radiographic ILD.

Conclusion In patients with SSc, Scl-70 positivity is a risk factor for FVC% predicted decline at 5 years. Esophageal dilation on HRCT was associated with a minimal, nonclinically significant decline in DLCO and no change in FVC during the 5-year follow-up. These results have prognostic implications for SSc-ILD patients with esophageal dilation.

Key Indexing Terms:
  • biomarkers
  • gastrointestinal disease
  • interstitial lung disease
  • systemic sclerosis

Interstitial lung disease (ILD) is a leading cause of death in patients with systemic sclerosis (SSc).1,2 Known risk factors for prevalent SSc-ILD include positive antitopoisomerase I (Scl-70) serum autoantibody status, diagnosis of diffuse cutaneous (dc)-SSc, Black race, male sex, and genetic polymorphisms including certain major histocompatibility complex (MHC) class II human leukocyte alleles (MHC-II HLA-DRB1*11 and HLA-DPB*1301), and non-MHC genes including those for interleukin (IL)-1α, and IL-1β.2 However, less is known regarding risk factors for SSc-ILD progression. A systematic review of 20 studies between 1994 and 2012 (1524 patients with SSc) found that greater chest high-resolution computed tomography (HRCT) fibrosis severity and shorter SSc disease duration were predictors of ILD progression.3 Subsequently, Liu, et al showed that baseline elevation in C-reactive protein predicted SSc-ILD progression, measured by change in % predicted forced vital capacity (FVC), over a mean time-in-study of 4.4 years.4 Assassi, et al demonstrated that positive Scl-70 autoantibody status was associated with short-term (3-yr) FVC% predicted decline (regression coefficient = –2.49, 95% CI –4.62 to –0.36, P = 0.02) in an SSc cohort where 58% had baseline FVC% predicted > 80. However, beyond 3 years, autoantibody status was not associated with progression, as assessed by FVC% predicted change.5

Symptomatic esophageal disease is present in > 50% of patients with SSc, and abnormal esophageal motility of uncertain significance on manometric testing is present in up to 90% of patients with SSc.6 Esophageal dilation (defined as > 10-mm diameter on coronal HRCT images) in patients with SSc is associated with esophageal dysmotility, as assessed by esophageal transit scintigraphy;7 further, esophageal dysmotility may be associated with SSc-ILD progression.1,8 Specifically, Marie, et al reported that in 43 patients with SSc-ILD, those with severe vs mild-to-moderate esophageal dysmotility on manometry demonstrated greater 2-year decline in % predicted diffusion capacity for carbon monoxide (DLCO; –16.04% vs 1.47%, P = 0.02), but not FVC% predicted (–3.65% vs 0.09%, P = 0.39).8 We previously showed in a cross-sectional study that esophageal diameter on axial HRCT images correlated positively with the presence of radiographic ILD and negatively with baseline FVC% and DLCO% predicted in patients with SSc.9 Moreover, an esophageal diameter ≥ 19 mm had the best combined sensitivity and specificity for associated radiographic SSc-ILD.10

Mechanistically, a dilated esophagus may act as a gastric content reservoir allowing for microaspiration that induces lung parenchymal damage.1,8,11,12 Gastroesophageal reflux disease is associated with idiopathic pulmonary fibrosis, and its treatment has been shown to stabilize lung function, supporting the hypothesis that esophageal dysfunction may also play an important role in SSc-ILD pathogenesis and progression.13,14 The present study was undertaken to determine if radiographic esophageal dilation is an independent risk factor for pulmonary function decline during 1, 2, and 5 years of follow-up in patients with SSc. We also sought to identify other important patient factors associated with SSc-ILD progression using our large cohort of clinically well-characterized patients with SSc.

METHODS

This retrospective study was approved by the Northwestern University Institutional Review Board (STU00066807). Patient consent was obtained through the Northwestern Scleroderma Patient Registry (STU00002669). Patients with sine scleroderma, limited cutaneous (lc-), or dcSSc who fulfilled American College of Rheumatology 2013 SSc classification criteria and had at least 1 HRCT and 2 pulmonary function tests (PFTs) were included.15 SSc disease duration was defined as the duration between first non-Raynaud SSc symptom and the baseline HRCT date. Follow-up time was defined as time from baseline PFT to last PFT date between April 2008 and August 2016. Patients with prior pulmonary or gastrointestinal (GI) procedures that would independently affect esophageal diameter or PFT measurements, including lung transplant, lobectomy, or esophageal dilatation procedures, were excluded. Important baseline clinical data were obtained by manual review of rheumatology clinic notes within 1 year of HRCT date. Collected data include proton pump inhibitor (PPI) use, prednisone use (any), tobacco use (current or former), digital ulcer (DU) history, pulmonary and GI symptoms, and erythrocyte sedimentation rate. Pulmonary arterial hypertension (PAH) was defined as mean pulmonary arterial pressure ≥ 25 mmHg on right heart catheterization.16

An experienced thoracic radiologist (RA), blinded to clinical data, manually reviewed HRCT exams to determine widest esophageal diameter (WED) and the presence or absence of ILD. The WED was defined as the largest of 3 esophageal diameters (mucosa to mucosa) at the level of the mid-arch of the aorta, the carina, and the diaphragmatic hiatus on axial HRCT images.9 Patients were dichotomized by WED ≥ 19 mm or < 19 mm because our previous results showed that a WED cutpoint of 19 mm had the highest combined sensitivity and specificity for prevalent radiographic SSc-ILD.10 The presence or absence of radiographic ILD was determined based upon methods described by Kazerooni, et al.9,17 PFT change was analyzed in the full cohort (regardless of ILD status), and subanalysis was performed in patients with baseline radiographic ILD. We evaluated interrater reliability (between 2 radiologists) and intrarater reliability (2 ratings of 1 radiologist) for WED using intraclass correlation coefficient (ICC) for 2-way random effects model and for ILD presence using Cohen κ coefficient and % agreement for a subset of 60 HRCT scans. The sample size of 60 was calculated expecting the estimated ICC to be ≥ 0.90 compared to the null ICC of 0.80 with at least 80% power and α of 0.05.

Baseline PFT was defined as the test closest to, and within 12 months of, the first available HRCT. Subsequent longitudinal PFT data were recorded in months from baseline HRCT. Using National Health and Nutrition Examination Survey III reference populations, predicted FVC was determined by age, sex, and race, and predicted DLCO was determined by age and sex, and adjusted for hemoglobin.18 The DLCO value was excluded from analysis in patients without an available hemoglobin result within 6 months of PFT or where inspiratory vital capacity (IVC):FVC ratio was < 0.85 (indicating poor test quality).19

We performed parallel analyses for FVC and DLCO change. For FVC analyses, we included 138 patients with FVC results and measured change in FVC% predicted to determine patient factors associated with longitudinal FVC decline. For DLCO analyses, we included 99 patients with DLCO results, and measured change in DLCO% predicted to determine patient factors associated with longitudinal DLCO decline. Both change in FVC% and DLCO% predicted were used as surrogates for worsening ILD.20,21 Clinically meaningful PFT worsening was defined as a ≥ 5-point decrease in FVC% predicted and/or a 15-point decrease in DLCO% predicted.8, 21–26

Spaghetti plots were used to visualize FVC% and DLCO% predicted change over time between Scl-70–positive vs –negative groups and WED ≥ 19 mm vs WED < 19 mm groups. We tested for baseline differences between those with vs without ILD progression using chi-square tests for categorical variables, and 2-sample t tests with unequal variance for continuous variables. We used linear mixed effects models with random intercepts and an unstructured covariance structure to examine between-group differences in FVC% and DLCO% predicted change over time. Time since baseline PFT was modeled with a linear term. We tested for group differences by including group*time interaction terms. We analyzed possible differences in FVC% and DLCO% predicted change by WED groups within Scl-70–positive patients by including a 3-way interaction. We presented means adjusted estimates from models adjusted for sex, SSc disease subtype, Scl-70 positivity, SSc disease duration, PPI use, prednisone use, and smoking history. All analyses were conducted using SAS version 9.4 (SAS Institute) and R version 3.5.3 (cran.r-project.org).

RESULTS

The cohort included 138 patients who fulfilled study criteria with a median (range) follow-up of 2.9 (0.3–7.2) years (Figure 1). Fifteen patients (11%) with baseline HRCT died. The median (range) time between last PFT and death was 1.4 (0.2–3.9) years. Baseline characteristics for the full cohort and for patients with baseline radiographic ILD are described in Table 1. Most patients were female (84%), White (75%), and nonsmokers (62%). The mean (SD) age was 50 (11.1) years, and modified Rodnan skin score was 11 (9). Scl-70 was positive in 50 of 138 (36%) patients, and 64 (46%) patients had dcSSc. Radiographic ILD was present in 100 out of 138 (72%) patients, of whom 48% had positive Scl-70 and 54% had dcSSc. The mean (SD) baseline FVC% predicted was 78 (16.7) and DLCO was 60 (20.4) in the full cohort. Among patients with baseline ILD, mean FVC% predicted was 75 (17.3) and DLCO was 57 (19.9). The mean (SD) WED was 17.6 (8.2) mm in the full cohort and 18.6 (7.8) mm among patients with radiographic ILD. The median (IQR) number of PFTs per patient was 3 (2–4).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Derivation of analysis sample. * Patients excluded for missing PFTs may have met multiple exclusion criteria. ACR: American College of Rheumatology; dcSSc: diffuse cutaneous systemic sclerosis; DLCO: diffusing capacity of the lung for carbon monoxide; FVC: forced vital capacity; HRCT: high-resolution computed tomography; IVC: inspiratory vital capacity; lcSSc: limited cutaneous systemic sclerosis; PFT: pulmonary function test; SSS: scleroderma sine scleroderma.

View this table:
  • View inline
  • View popup
Table 1.

Baseline characteristics of full study cohort and patients with baseline radiographic SSc-associated ILD.

Reliability. Because the presence of ILD is based upon clinical judgment, 2 independent assessors reviewed a subset of chest HRCT exams. The interrater reliability κ was 0.96 (95% CI 0.88–1.00) for ILD presence, and ICC was 0.97 (95% CI 0.94–0.98) for WED. The intrarater reliability κ was 0.83 (95% CI 0.67–0.99) for ILD, and ICC was 0.97 (95% CI 0.95–0.98) for WED.

Baseline characteristics and clinically meaningful pulmonary function change. We compared baseline characteristics between patients with and without meaningful change in FVC (≥ 5-point change) and DLCO (≥ 15-point change; Table 2 and Table 3). In both the full study cohort and among patients with baseline radiographic SSc-ILD, positive Scl-70 status was more common in patients with vs without FVC worsening (full cohort: 51% vs 28%, P = 0.01; radiographic ILD only: 62% vs 39%, P = 0.05). Among patients with baseline radiographic ILD, those with meaningful FVC change less commonly had DUs present (26% vs 49%, P = 0.03). Baseline FVC% predicted was lower in those who demonstrated significant DLCO decline (full cohort: 67 vs 78, P = 0.03; radiographic ILD only: 64 vs 76, P = 0.04). There was no difference in the presence of PAH in those with vs without longitudinal DLCO decline.

View this table:
  • View inline
  • View popup
Table 2.

Baseline characteristics of patients with systemic sclerosis with vs. without clinically meaningful %-predicted FVC worsening.

View this table:
  • View inline
  • View popup
Table 3.

Baseline characteristics of patients with systemic sclerosis with vs without clinically meaningful DLCO% predicted worsening.

Longitudinal pulmonary function change by Scl-70 status. In the full cohort, baseline FVC% predicted was lower in those with positive vs negative Scl-70 status (72, 95% CI 68–77 vs 82, 95% CI 79–86, respectively; P < 0.01). There was a statistically significant decline in FVC% predicted at 1, 2, 3, and 5 years in patients with positive Scl-70 status (5-yr change: –6.33, 95% CI –9.87 to –2.79, P < 0.01), adjusted for sex, PPI use, prednisone use, SSc disease subtype, SSc disease duration, smoking history (current or former), and WED (Table 4, Figure 2). In those lacking Scl-70, there was no significant change in FVC% predicted in the adjusted model (1.78, 95% CI –0.59 to 4.15, P = 0.14). The reverse was observed for DLCO% predicted change where patients lacking Scl-70 demonstrated a statistically significant modeled change in DLCO% predicted from baseline to 1, 2, 3, and 5 years (5-yr change: –3.31, 95% CI –6.57 to –0.05) that did not meet the prespecified clinical threshold for significance. Patients with positive Scl-70 lacked significant change in DLCO% predicted over time (5-yr change: –4.65, 95% CI –10.96 to 1.65; Table 4, Figure 2). Similar findings were observed when restricting the analysis to only those with radiographic ILD at baseline (Figure 2B; Supplementary Table 1, available with the online version of this article).

View this table:
  • View inline
  • View popup
Table 4.

Model-based estimates for change over time in FVC% (n = 138) and DLCO% predicted (n = 99) in patients with SSc by Scl-70 and WED (95% CI)a.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Change in pulmonary function by Scl-70 autoantibody status and WED. (A) Analysis of the full cohort (n = 138). (B) Analysis of the subset of patients with interstitial lung disease on baseline high-resolution computed tomography scan (n = 100). Spaghetti plot depicting change in FVC% (n = 138) and DLCO% predicted (n = 99) over time in patients with SSc. Thick lines represent estimated FVC% and DLCO% predicted from statistical model using data from all patients. DLCO: diffusing capacity of the lung for carbon monoxide; FVC: forced vital capacity; Scl-70: antitopoisomerase I; SSc: systemic sclerosis; WED: widest esophageal diameter.

Longitudinal pulmonary function change by WED. Baseline characteristics for patients with a WED ≥ 19 vs < 19 mm are shown in Supplementary Table 2 (available with the online version of this article). At baseline, radiographic ILD was more common in patients with WED ≥ 19 vs < 19 mm (52 of 64 [81%] vs 48 of 74 [65%], P = 0.03). The baseline mean FVC% predicted was lower in WED ≥ 19 compared to those with WED < 19 mm (73 vs 82, P < 0.01). Similarly, the baseline mean DLCO% predicted was lower in the wider (vs narrower) WED group (57 vs 64, P = 0.05). The mean follow-up time was similar for individuals with WED ≥ 19 vs < 19 (3.1 and 3.0 yrs, respectively).

Longitudinally, patients with WED ≥ 19 mm demonstrated a small, statistically significant DLCO% predicted change from baseline to 5 years (–5.58, 95% CI –10.00 to –1.15; Table 4, Figure 2), adjusted for sex, PPI use, prednisone use, SSc disease subtype, SSc disease duration, smoking history (current or former), and Scl-70 status. There was no statistically significant difference in FVC% predicted change in patients dichotomized by esophageal diameter (Table 4, Figure 2). Similar findings were observed when restricting the analysis to only patients with baseline radiographic ILD (Figure 2; Supplementary Table 3, available with the online version of this article). Testing the 3-way interaction of Scl-70 status, WED, and time showed there was no significant difference in FVC decline among patients with positive Scl-70 status comparing WED ≥ 19 vs < 19 mm (difference in change from baseline to 5 yrs = –3.17, 95% CI –11.14 to 4.79).

DISCUSSION

To determine the effect of esophageal dilation on SSc-ILD progression, we examined a large cohort of 138 well-characterized patients with SSc who had undergone HRCT and serial PFT. We showed that esophageal dilation on axial chest HRCT images was associated with a minimal, nonclinically significant decline in DLCO and no change in FVC during the 5-year follow-up, and Scl-70 is associated with SSc-ILD worsening as assessed by FVC and/or DLCO decline. In patients with SSc, Savarino, et al reported an association between greater number of proximal reflux episodes on pH impedance testing and pulmonary fibrosis on HRCT, supporting the hypothesis that esophageal dysfunction is related to SSc-ILD.27 Similarly, in a previous study, we showed that a larger WED was associated with prevalent radiographic SSc-ILD and lower FVC% and DLCO% predicted.9,10 However, in the present study, a dilated esophagus on HRCT did not predict longitudinal FVC worsening. Winstone, et al,28 who studied 145 patients with SSc (median follow-up 4 yrs), reported that for every 1-cm increase in esophageal diameter on chest HRCT at baseline, there was a 1.8% higher lung fibrosis score and 5.5% lower FVC% predicted (P < 0.001) after adjustment for age, sex, weight, and BMI. However, there was no association between esophageal diameter and change in FVC% predicted at 1-year follow-up when adjusting for baseline fibrosis score.28 Our study included DLCO% predicted, which some consider to better estimate ILD extent, as discussed below, and we tested a proposed WED threshold of 19 mm as an esophageal dilation cutpoint that could be important to include in chest HRCT reports in patients with SSc.

We demonstrate that the presence of Scl-70 autoantibodies was associated with FVC but not DLCO worsening over a 2.9-year median follow-up period. Assassi, et al reported that positive Scl-70 status was associated with short-term (3-yr) decline in FVC% predicted in 244 patients with SSc.5 We found a statistically significant (though not likely clinically meaningful) decline in DLCO% predicted in patients without Scl-70. This finding may be because DLCO decline is less specific for ILD and can be observed in SSc-associated PAH.29

We report a 73% ILD prevalence in our cohort that is similar to other tertiary care center rates (36–84%).30,31,32 Our prevalence on the upper end of this reported range is likely a result of selection bias due to inclusion criteria requiring patients to have an available chest HRCT. Although many patients undergo HRCT at the baseline visit, it is not standard of care for all patients at our center. Thus, HRCT may be obtained more frequently in patients with pulmonary symptoms or abnormal physical exam findings in whom ILD is present. Further, only 51 of 138 (37%) patients we studied demonstrated clinically meaningful FVC worsening. Reasons for FVC stability may be related to high baseline FVC% predicted, reflecting more mild disease or the use of medications including mycophenolate mofetil and cyclophosphamide for ILD in approximately 30% of patients at the time of baseline HRCT scan.20,33 In this retrospective study, we were unable to assess the longitudinal use of ILD medications that may have stabilized pulmonary function and confounded the relationship with esophageal diameter and ILD. Thus, patients may have received ILD therapies after the baseline HRCT exam. Another possible reason for stability is the interdisciplinary care provided at our SSc program that includes aggressive use of PPIs, lifestyle management counseling including head-of-bed elevation, avoidance of meals before recumbency, and importance of attaining/maintaining ideal body weight (the mean BMI of our group was 26 [SD 5.73]). The control of GI reflux with acid suppressive therapy and counseling may be associated with a slower rate of FVC decline.34,35 We also did not classify patients by ILD pattern (usual interstitial pneumonia vs fibrotic nonspecific interstitial pneumonia), which could have affected PFT trajectory.

In this study, we defined clinically meaningful PFT worsening a priori as ≥ 5-point decrease in FVC% predicted or 15-point decrease in DLCO% predicted.8, 21–26 We chose FVC% predicted change ≥ 5 as an intermediate threshold based upon studies using a range of FVC change between 2 and 10 to define meaningful change. Specifically, in idiopathic pulmonary fibrosis, a 2- to 6-point decline in FVC% predicted is defined as clinically meaningful.24 Based on the Scleroderma Lung Study (SLS)-I and SLS-II, clinically meaningful change in FVC% predicted at 12 months could be considered as low as an FVC decline of 3–3.3%,25 whereas the Outcomes in Rheumatology (OMERACT) Connective Tissue Disease-ILD Working Group suggest FVC decline ≥ 10% to define progression.26 Compared to SLS-I and SLS-II and the nintedanib trial36that each followed patients for only 1 year, our median follow-up was 2.9 years. Regarding DLCO, some studies suggest that DLCO best estimates SSc-ILD extent, although the potential lack of specificity and reproducibility limits its use as an outcome.37,38 Future studies may help determine the minimal clinically important differences in FVC and DLCO, specifically in patients with SSc.

Our study has limitations. As an observational study, no conclusions regarding the causality of esophageal dilation and ILD progression can be inferred, and patient follow-up and PFT timing is not uniform. Also, mean SSc disease duration at the time of HRCT is 5.7 years in the full cohort (4.7 yrs among those with baseline radiographic ILD), which limits assessment of early pulmonary function decline and may enrich our cohort for patients with more stable disease. The relatively high mean baseline FVC% predicted of 75 for patients in our cohort limits our ability to identify patient factors that are associated with longitudinal FVC decline in patients with more severe pulmonary disease at baseline. Also, patients did not routinely undergo esophageal manometry, so we are unable to comment on the relationship between esophageal diameter and dysfunction. Additionally, we defined esophageal dilation as ≥ 19 mm, because we previously found that this cutpoint has the best combined sensitivity and specificity for SSc-ILD. Previous studies investigating esophageal dilation effect on pulmonary function defined esophageal dilation as ≥ 10 mm, based on radiographic definitions of “normal,” and found no association with esophageal dilation and ILD.7 Our definition, while more precisely related to SSc-ILD, may misclassify some patients with a more mildly dilated esophagus (10–18 mm) and bias our results toward the null hypothesis (no difference in FVC decline between groups). Only 1 expert radiologist determined if radiographic ILD was present vs absent, which is the standard for clinical care.

Study strengths include examination of FVC% and DLCO% predicted as surrogates for worsening pulmonary disease in a sample of well-characterized patients with SSc. Study coordinators routinely contact outside hospitals to obtain serum autoantibody serologies and PFT records to reduce ascertainment bias. The DLCO measurement accuracy was assured by adjusting for hemoglobin, and by excluding patients for whom a complete blood count was not available in the preceding 6 months and for whom the IVC:FVC ratio was < 0.85, because these features improve DLCO accuracy. Excluding patients with poor-quality DLCO data or lacking hemoglobin values within 6 months may have introduced selection bias; however, inclusion of these patients would introduce error into the DLCO measurement. Other strengths include the large study size and the evaluation of esophageal diameter as a potential novel predictor for SSc-ILD progression. Also, an expert thoracic radiologist performed all esophageal diameter measurements on axial images and identified the largest diameter among 3 locations: mid-arch of the aorta, the carina, and the diaphragmatic hiatus. This allowed us to more accurately classify patients by esophageal diameter.

Scl-70 autoantibody positivity is a risk factor for FVC% predicted decline in patients with SSc. Esophageal dilation on HRCT was associated with a minimal, nonclinically significant 5-year decline in DLCO% predicted and no change in FVC% predicted during follow-up. These results have prognostic implications for SSc-ILD patients with esophageal dilation. Prospective studies that enroll patients with early SSc disease such as the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) and Prospective Registry of Early Systemic Sclerosis (PRESS) registries will enable identification of the relationship between esophageal diameter and early PFT decline and may identify other patient factors and/or biomarkers associated with ILD progression.39,40

Footnotes

  • Research was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (NIH) under Award Numbers K23 AR059763 (MH), R01 AR073270 (MH), P60 AR064464 (RWC, KS, JL), and P30 AR072579 (RWC, JL), and National Center for Advancing Translational Sciences-Clinical and Translational Science Award Number UL1 TR000150 (JL). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The Rheumatology Research Foundation (KS), Scleroderma Foundation (KS), and the Scleroderma Research Foundation (MH) also supported this work.

  • The authors declare no conflicts of interest relevant to this article.

  • Accepted for publication July 8, 2021.
  • Copyright © 2021 by the Journal of Rheumatology

REFERENCES

  1. 1.↵
    1. Christmann RB,
    2. Wells AU,
    3. Capelozzi VL,
    4. Silver RM
    . Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence. Semin Arthritis Rheum 2010;40:241–9.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Wells AU
    . Interstitial lung disease in systemic sclerosis. Presse Med 2014;10 Pt 2:e329–43.
    OpenUrl
  3. 3.↵
    1. Winstone TA,
    2. Assayag D,
    3. Wilcox PG,
    4. Dunne JV,
    5. Hague CJ,
    6. Leipsic J, et al
    . Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest 2014;146:422–36.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Liu X,
    2. Mayes MD,
    3. Pedroza C,
    4. Draeger HT,
    5. Gonzalez EB,
    6. Harper BE, et al
    . Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis? Arthritis Care Res 2013;65:1375–80.
    OpenUrlCrossRef
  5. 5.↵
    1. Assassi S,
    2. Sharif R,
    3. Lasky RE,
    4. McNearney TA,
    5. Estrada YMRM,
    6. Draeger H, et al; GENISOS Study Group
    . Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther 2010;12:R166.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Sjogren RW
    . Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 1994;37:1265–82.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Pitrez EH,
    2. Bredemeier M,
    3. Xavier RM,
    4. Capobianco KG,
    5. Restelli VG,
    6. Vieira MV, et al
    . Oesophageal dysmotility in systemic sclerosis: comparison of HRCT and scintigraphy. Br J Radiol 2006; 79:719–24.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Marie I,
    2. Dominique S,
    3. Levesque H,
    4. Ducrotte P,
    5. Denis P,
    6. Hellot MF, et al
    . Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum 2001;45:346–54.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Richardson C,
    2. Agrawal R,
    3. Lee J,
    4. Almagor O,
    5. Nelson R,
    6. Varga J, et al
    . Esophageal dilatation and interstitial lung disease in systemic sclerosis: a cross-sectional study. Semin Arthritis Rheum 2016;46:109–14.
    OpenUrl
  10. 10.↵
    1. Hoffmann A,
    2. Lee J,
    3. Ma M,
    4. Agrawal R,
    5. Chang RW,
    6. Richardson C, et al
    . Comment on “esophageal dilatation and interstitial lung disease in systemic sclerosis: a cross-sectional study”. Semin Arthritis Rheum 2016;46:e11–2.
    OpenUrl
  11. 11.↵
    1. Johnson DA,
    2. Drane WE,
    3. Curran J,
    4. Cattau EL, Jr.,
    5. Ciarleglio C,
    6. Khan A, et al
    . Pulmonary disease in progressive systemic sclerosis. A complication of gastroesophageal reflux and occult aspiration? Arch Intern Med 1989;149:589–93.
    OpenUrl
  12. 12.↵
    1. Lock G,
    2. Pfeifer M,
    3. Straub RH,
    4. Zeuner M,
    5. Lang B,
    6. Scholmerich J, et al
    . Association of esophageal dysfunction and pulmonary function impairment in systemic sclerosis. Am J Gastroenterol 1998;93:341–5.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Lee JS,
    2. Collard HR,
    3. Raghu G,
    4. Sweet MP,
    5. Hays SR,
    6. Campos GM, et al
    . Does chronic microaspiration cause idiopathic pulmonary fibrosis? Am J Med 2010;123:304–11.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Raghu G,
    2. Yang ST,
    3. Spada C,
    4. Hayes J,
    5. Pellegrini CA
    . Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest 2006;129:794–800.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. van den Hoogen F,
    2. Khanna D,
    3. Fransen J,
    4. Johnson SR,
    5. Baron M,
    6. Tyndall A, et al
    . 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2013;65:2737–47.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Galie N,
    2. Hoeper MM,
    3. Humbert M,
    4. Torbicki A,
    5. Vachiery JL,
    6. Barbera JA, et al; ESC Committee for Practice Guidelines (CPG)
    . Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493–537.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Kazerooni EA,
    2. Martinez FJ,
    3. Flint A,
    4. Jamadar DA,
    5. Gross BH,
    6. Spizarny DL, et al
    . Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997;169:977–83.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Hankinson JL,
    2. Odencrantz JR,
    3. Fedan KB
    . Spirometric reference values from a sample of the general U.S. Population. Am J Respir Crit Care Med 1999;159:179–87.
    OpenUrlCrossRef
  19. 19.↵
    1. Macintyre N,
    2. Crapo RO,
    3. Viegi G,
    4. Johnson DC,
    5. van der Grinten CP,
    6. Brusasco V, et al
    . Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005;26:720–35.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Tashkin DP,
    2. Roth MD,
    3. Clements PJ,
    4. Furst DE,
    5. Khanna D,
    6. Kleerup EC, et al; Sclerodema Lung Study II Investigators
    . Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016;4:708–19.
    OpenUrl
  21. 21.↵
    1. Goh NS,
    2. Hoyles RK,
    3. Denton CP,
    4. Hansell DM,
    5. Renzoni EA,
    6. Maher TM, et al
    . Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol 2017;69:1670–8.
    OpenUrlPubMed
  22. 22.
    1. Goh NS,
    2. Desai SR,
    3. Anagnostopoulos C,
    4. Hansell DM,
    5. Hoyles RK,
    6. Sato H, et al
    . Increased epithelial permeability in pulmonary fibrosis in relation to disease progression. Eur Respir J 2011;38:184–90.
    OpenUrlAbstract/FREE Full Text
  23. 23.
    1. Bouros D,
    2. Wells AU,
    3. Nicholson AG,
    4. Colby TV,
    5. Polychronopoulos V,
    6. Pantelidis P, et al
    . Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002;165:1581–6.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. du Bois RM,
    2. Weycker D,
    3. Albera C,
    4. Bradford WZ,
    5. Costabel U,
    6. Kartashov A, et al
    . Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011;184:1382–9.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Kafaja S,
    2. Clements PJ,
    3. Wilhalme H,
    4. Tseng CH,
    5. Furst DE,
    6. Kim GH, et al
    . Reliability and minimal clinically important differences of forced vital capacity: results from the scleroderma lung studies (SLS-I and SLS-II). Am J Respir Crit Care Med 2018;197:644–52.
    OpenUrlPubMed
  26. 26.↵
    1. Khanna D,
    2. Mittoo S,
    3. Aggarwal R,
    4. Proudman SM,
    5. Dalbeth N,
    6. Matteson EL, et al
    . Connective tissue disease-associated interstitial lung diseases (CTD-ILD) – report from OMERACT CTD-ILD working group. J Rheumatol 2015;42:2168–71.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Savarino E,
    2. Bazzica M,
    3. Zentilin P,
    4. Pohl D,
    5. Parodi A,
    6. Cittadini G, et al
    . Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med 2009;179:408–13.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Winstone TA,
    2. Hague CJ,
    3. Soon J,
    4. Sulaiman N,
    5. Murphy D,
    6. Leipsic J, et al
    . Oesophageal diameter is associated with severity but not progression of systemic sclerosis-associated interstitial lung disease. Respirology 2018;23:921–6.
    OpenUrl
  29. 29.↵
    1. Steen V
    . Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis 2003;62:97–9.
    OpenUrlFREE Full Text
  30. 30.↵
    1. Steele R,
    2. Hudson M,
    3. Lo E,
    4. Baron M, Canadian Scleroderma Research Group
    . Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Arthritis Care Res 2012;64:519–24.
    OpenUrlCrossRef
  31. 31.↵
    1. Suliman YA,
    2. Dobrota R,
    3. Huscher D,
    4. Nguyen-Kim TD,
    5. Maurer B,
    6. Jordan S, et al
    . Brief report: pulmonary function tests: high rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease. Arthritis Rheumatol 2015;67:3256–61.
    OpenUrl
  32. 32.↵
    1. Vonk MC,
    2. van Die CE,
    3. Snoeren MM,
    4. Bhansing KJ,
    5. van Riel PL,
    6. Fransen J, et al
    . Oesophageal dilatation on high-resolution computed tomography scan of the lungs as a sign of scleroderma. Ann Rheum Dis 2008;67:1317–21.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Tashkin DP,
    2. Elashoff R,
    3. Clements PJ,
    4. Goldin J,
    5. Roth MD,
    6. Furst DE, et al; Scleroderma Lung Study Research Group
    . Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655–66.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Lee JS,
    2. Collard HR,
    3. Anstrom KJ,
    4. Martinez FJ,
    5. Noth I,
    6. Roberts RS, et al; IPFnet Investigators
    . Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med 2013;1:369–76.
    OpenUrl
  35. 35.↵
    1. Lee JS,
    2. Ryu JH,
    3. Elicker BM,
    4. Lydell CP,
    5. Jones KD,
    6. Wolters PJ, et al
    . Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184:1390–4.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Distler O,
    2. Highland KB,
    3. Gahlemann M,
    4. Azuma A,
    5. Fischer A,
    6. Mayes MD, et al; SENSCIS Trial Investigators
    . Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med 2019;380:2518–28.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Tashkin DP,
    2. Volkmann ER,
    3. Tseng CH,
    4. Kim HJ,
    5. Goldin J,
    6. Clements P, et al
    . Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. Ann Rheum Dis 2016;75:374–81.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Caron M,
    2. Hoa S,
    3. Hudson M,
    4. Schwartzman K,
    5. Steele R
    . Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease. Eur Respir Rev 2018;27:170102.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. Frech TM,
    2. Shanmugam VK,
    3. Shah AA,
    4. Assassi S,
    5. Gordon JK,
    6. Hant FN, et al
    . Treatment of early diffuse systemic sclerosis skin disease. Clin Exp Rheumatol 2013;2 Suppl 76:166–71.
    OpenUrl
  40. 40.↵
    1. Minier T,
    2. Guiducci S,
    3. Bellando-Randone S,
    4. Bruni C,
    5. Lepri G,
    6. Czirjak L, et al; EUSTAR co-workers
    . Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis 2014;73:2087–93.
    OpenUrlAbstract/FREE Full Text

ONLINE SUPPLEMENT

Supplementary material accompanies the online version of this article.

PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 48, Issue 12
1 Dec 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Esophageal Dilation and Other Clinical Factors Associated With Pulmonary Function Decline in Patients With Systemic Sclerosis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Esophageal Dilation and Other Clinical Factors Associated With Pulmonary Function Decline in Patients With Systemic Sclerosis
Kimberly Showalter, Aileen Hoffmann, Carrie Richardson, David Aaby, Jungwha Lee, Jane Dematte, Rishi Agrawal, Hatice Savas, Xiaoping Wu, Rowland W. Chang, Monique Hinchcliff
The Journal of Rheumatology Dec 2021, 48 (12) 1830-1838; DOI: 10.3899/jrheum.210533

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Esophageal Dilation and Other Clinical Factors Associated With Pulmonary Function Decline in Patients With Systemic Sclerosis
Kimberly Showalter, Aileen Hoffmann, Carrie Richardson, David Aaby, Jungwha Lee, Jane Dematte, Rishi Agrawal, Hatice Savas, Xiaoping Wu, Rowland W. Chang, Monique Hinchcliff
The Journal of Rheumatology Dec 2021, 48 (12) 1830-1838; DOI: 10.3899/jrheum.210533
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • REFERENCES
    • ONLINE SUPPLEMENT
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • References
  • PDF
  • eLetters

Keywords

BIOMARKERS
gastrointestinal disease
INTERSTITIAL LUNG DISEASE
SYSTEMIC SCLEROSIS

Related Articles

Cited By...

More in this TOC Section

  • Timing and Predictors of Incident Cardiovascular Disease in Systemic Lupus Erythematosus: Risk Occurs Early and Highlights Racial Disparities
  • Patient Acceptable Symptom State for Burden From Appearance Changes in People With Systemic Sclerosis: A Cross-sectional Survey
  • Impaired Fibrinolysis Is Linked With Digital Vasculopathy and Onset of New Digital Ulcers in Systemic Sclerosis
Show more Systemic Sclerosis

Similar Articles

Keywords

  • biomarkers
  • gastrointestinal disease
  • interstitial lung disease
  • systemic sclerosis

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire